Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Carragelose based nasal sprays have been outlicensed for the Brazilian and Mexican markets. Marinomed has entered into an exclusive license agreement with M8 Pharmaceuticals (formerly moksha8). M8 is a specialty pharmaceutical company focused on licensing, marketing, and distributing innovative and established therapeutics in the two largest Latin American markets, Brazil and Mexico. M8 will be responsible for pursuing the local approvals in Brazil and Mexico, after which the Carragelose nasal spray will be launched under the trade name Barlo®, further expanding the geographical reach. Carragelose products are already available without prescription (OTC) in more than 40 countries. Carragelose has a clinically proven high efficacy in preventing infection and viral spread of multiple respiratory viruses including both endemic Corona viruses such as OC43 as well as SARS-CoV-2.
“An agreement with a partner as experienced and strong on the Latin American markets like M8 underlines Marinomed’s increasing recognition and helps us to expand the global reach of Carragelose,” said Dr. Andreas Grassauer, CEO of Marinomed. "We strongly believe that the antiviral efficacy of Carragelose, inactivating SARS-CoV-2 independently of the actual variant, can make an important contribution in combating the pandemic, supporting the preventative hygiene measures taken worldwide.”